Comments
Homegrown pharma major Lupin Ltd today announced the launch of a generic version of its voriconazole tablets and oral suspension used for the treatment of fungal infections in children.
Having received approval from the US Food and Drug Administration (USFDA) earlier to market a generic equivalent of PF Prism CV’s Vfend tablets, 50 mg and 200 mg and Vfend Oral Suspension 40 mg/mL, the company said it had launched the same in the US market.
The medicines are indicated for use in patients 12 years of age and older in the treatment of fungal infections, including invasive Aspergillosis, Candidemia in non-neutropenic patients.
Besides, it is also used for treatment of Candida infections in skin, and infections in the abdomen, kidney, bladder wall and wounds, among others.
Citing IMS MAT September 2016 data, the company said Vfend Tablets, 50mg & 200mg had US sales of $81 million, while Vfend Oral Suspension, 40 mg/mL, had US sales of $15.2 million.
Shares of Lupin Ltd were trading at Rs 1,480.50 apiece at mid-day, up 0.81 per cent from the previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.